the joining Thanks, everyone, Good call. for afternoon.
the for in achieve first-mover on and scientific to of first how will and personalized strategy results quarter key pipeline wellness financials. growing our quarter of expect creation milestones XXXX touch provide of on Today, our our And us rest Thorne's then the progress first I'll overview our field shareholders. key including brief I'll finally, review provide we in year. discuss strategies, unique the the core outlook accomplishments XXXX. of pathway quarter then key value review puts during positioning of growth financial then our sustainable for and programs detailed our and I'll a in a a advantage and Saloni strategic
As be Thomas details mentioned, closed. release after can market and in found supplement additional earnings the the investor issued
let's takeaway from The the is that, With dive overarching this. quarter in.
Our well we operating first during the call. executed internal the earnings targets against last performance plan was laid in strong, quarter and we and out our our
a for which we the reaffirming result, XXXX, of a our we'll are details on. guidance full-year As discuss bit later
delving into Thorne's specifics is scientific wellness. first-mover of by the creating wellness science delivering to Before and describing personalized performance, HealthTech. health There begin solutions other unique quarter on company a individual first broad advancing store solutions range for first in of and across and like no level advantage technology-driven that personalized I'd is our channels such
suppliers. portfolio. and a And significant that technology, continues personalized are supported pure improve, at analytics data to gives the of product to highly portfolio a including product rigorous supplement of We the generate AI-based wellness, the trial clinical to applying scientific forefront the rigor biopharma us of advantage latest differentiated by bringing quality our relative truly increasingly
professionals diverse for BXC Our and base to the experiencing customers expanding athletes. we marketplace to client professional in the care success reflects are health
across resonating solutions are individualized provides multiple brand needs support base, clearly build of personalized that offerings data, and and resources customer to life stage. health our products These portfolio and enabling educational our and customized goals every deep with us age Our in specific awareness channels. grow
technology making by wellness the investments solutions. R&D advantage that targeted increase in competitive personalized this will next-generation maintaining we're Importantly, of
last the With new anticipate comprehensive and investment, major strategy each a distribution the to over maintain this should our the X developed a a advantage are in filings advantage customers. to by across our comprises R&D insights these as applying perspective, generating for to data the confers three Our often competitive the of bioinformatics data which advantage companies pure model. year, produced products NDI limited large foreseeable clinical of three clinical cornerstone launch AI-based XX learnings significant years. put of multiphase a a relative to to has level platform extract us future. To to to competitive more in from data pipeline trials, sustainable are using our continuing than Thorne test includes who four R&D Thorn Many active other and operating investment we that sets products now that enable taken
understand story that data. pieces prove I some to to products our our the devices this to criticism time. is we takes primary to and excellence supplement even a the the This And assure the accomplish are and want wellness We to investors the but not bring But complex. space, space deep in that testing bit the by goals personalization need consumer is continue work journey unfortunately assemble customer and science our that scientific is advertised. bring to of only we companies and backed need space. to
decision-making create things way short-term We time our is business doing to around regulated platform. moats dealing that right real are lead in over believe the markets to could by and way only the where trouble
existing We we to we products. investors new can a of also same have this our to believe is across spectrum inform become but communicate maximize the hopefully our story shareholder that need we the them to so both broader that that and understand devoted customers way in value, way best
announced and quarter trial recent collaborative of a QX supplement of SynaQuell function productive positive brain hockey findings studying and a Thorne. as Clinic ice double-blind was the This effects result Tech on In we and for significant busy dietary with the to and early trial Mayo developments. structure Connect. April, randomized Turning Health junior players.
as provides portfolio to rights which acquired study, and scientific advisory SynaQuell provided the world-class results pleased we which of members. board has the with through to January, us access health in our our reminder, PreCon We're of very Health, brain that area acquisition nutritional evidence a As this portfolio. minutes, details strengthened SynaQuell support a supplement and a significance more such brain structure multi-ingredient clinical function. And I'll healthy product provide remains Minto's a the in on clear with of core few This focus cognitive filings. can these
of XX happy we're We to economic a finance ranks and management Saloni Officer. over wealth multiple of have the of strengthened functions, also Financial across talent her on our appointment with the and senior brings very Thorne, the With Varma experience Chief and of as years to expertise board. Saloni
note Fast the of to innovative world's Company's Annual XXXX. that I'm companies also were named pleased List most to for we
base. ability I apply Thorne's high-value As wellness advanced in the forefront a solutions that by results have positioned beginning can of innovation, within and technology our wellness. of for is at customer specifically the continue diverse said scientific upon health to that Recognition in consumers' the be the category approach across my our transforming personalized based Company reflects growing an achievements Fast honor and wellness remarks, our to and we delivered to and at wellness success
nicotinamide holding a U.S. Appeals property that Thorne's announced intellectual challenge ruling of final riboside issued the we prior of claim. Court Finally,
to the or synthetic to a that a relates of XXX reminder, riboside pharmaceutical compositions issued isolated from cover attempted source. to broadly natural previously patent a nicotinamide this As patent ruling referred as either
its this supplement behind the highly successful ruling favorable us, with products. marketplace the riboside of Mala continues expansion Thorne With into nutritional nicotinamide court suite
ongoing has performance. human NR safety Our and to several is great subject the a aging, related profile healthy of trials clinical cognition and
catalysts and some to briefly our discuss now upcoming XXXX. of remainder programs of I'd as key for the like milestones
chains single-use called A OneDraw redefine that hydrogel uses blood to vacuum. remain very device, health lab By cold We the lightweight to and device for the recommendations draw insights the is and OneDraw. to technology is poised viewed blood is excited the painless FDA-cleared, device attaches requiring processing on upper their of believe removing buttons cartridge an health, results, individuals our stable about analysis a on enables improved cartridge is capillary by mailed sample experience. and within with the the blood can blood storage. small, arm a patient we intelligence without that health our their A experience. then collection short, third-party within adhesive patients which collection device, preserve by unique two OneDraw sample platform In blood collected better on obstacles taking device the from control an prevent offering and better pressing advanced healthcare that virtually sample be a ultimately OneDraw the the professional. dry to for the and
blood in Patients a less pain had participants of greater capturing trial use thousands with reported sample. of OneDraw clinical in and significantly high-quality ease a large
to as been accessible in reach Biden's the remotely; research to in-person project then In participation recruit struggle difficult program the attend us health addition, more us making OneDraw conduct been used by previously increase OneDraw studies Moonshot studies to enabling allowed also has and Cancer of future SpaceX. space clinic. would have led and to to President an some those
mentioned and this To X, services announce MedTech past MedTech recognize device the To creativity, success of and May best health I put to health and Breakthrough awards nominations point, and and mission we prestigious OneDraw medical wellness hard excellence globally is portfolio the Awards solutions. digital that won of overall opening year, MedTech lies the award around at Breakthrough companies, Award proud in of received As in X,XXX to our of for technology remarks, for this innovation, program. work world. its XXXX the heart my context, that The on honor technology underscore the device. medical were almost products the
so health many and speaks level to So to an potential bodies. this device potential amazing achievement, for is and improving devices for among recognized of OneDraw the innovation care which
applications expand convenient we a lab from free plasma the on for can upcoming unsupervised expect which tests, separation while HealthTech's direct-to-consumer utilization to approval including this quarter. studying for we cartridge, catalysts, We FDA to cold-chain a hear sample are Thorne potential medical transport. of new the on earnings of back preserving currently during massive believe the prior opportunity the noted With near-term OneDraw our will third additional the As OneDraw, application unlock use portfolio of call, of device. respect of
wellness, will a are to patient-centric Looking further program OneDraw and health settings as only next the device increasingly approach contribute telehealth critical anticipate personalized looking Needless into aging focus clinical bringing we to differentiated from to the to longevity not wellness. say, it's also the decentralized phase of care we scientific but out, core to forward to of personalized trials. healthy our
prevent a SynaQuell for is athletes has function, co-developed neurologists health brain provide that help been with our to More support and some overview has especially to individuals at post-concussion metabolism, to other concussions support function structure supporting like as concussive from cognitive on blend specifically, and now brain arising and and designed for engaged a impacts. I'd Mayo Institute high-contact cell nutrient it well been update recovery in brief activities. program. enhanced SynaQuell as
focus evaluated noted hockey the daily Participants I pleased a a brain of earlier positive for SynaQuell course XX that double-blinded, the measured in that over As junior course and then announce trial were testing April, placebo SynaQuell placebo-controlled a in the to consumed ice brain At and went we study the same through the functions were function selective function of over the compared. function of those with whether players impact affect to head of processing could mechanisms to of nutritional beginning season. Brainwave collaboration favorably study baseline brain their associated speeds. specific specific duration Mayo action in either at season. latency, season. The the hockey end The tests Clinic Thorne's address was season, with the the designed purpose visual their performed included supplement the and determine the attention of results of a repeated of study, or
function Group all the participants, speed. history over and processing important concussions, without SynaQuell group improvement and the in a of with measures brain placebo showed those notable For brain prior of
the the first damage the in and a positive visual unmet from products and program Generating SynaQuell sports, these brain members group, participants is goal. had concussions athletes X when through sports-related X.X annually, significant has addresses positive of military, This provides SynaQuell which studies engaged of most by includes of medical high-quality were believe words, suffer and achieved victims estimated contact there and key stimuli, many a victims significant to history who neurofilament effect pictures auditory assess concussions, Group a SynaQuell's the products It's domestic important engaged a opportunity health comparing to high-impact is well-controlled SynaQuell risks of processing accident impacts Based on and In for well-designed evidence need the are who demonstrating value that and million the people sport. of abuse. market neuronal and clinical natural clinical data million and SynaQuell we patented. changes our unlike between in which has address demonstrating including results, gestures. study on to faced this clearly the significant placebo levels, light our people
Let Health program. technology, we're targets to white me progress of health be is patent-pending the enable provide and it. with of discover microbiome detailed sample a and a the wellness. Thorne's made test optimize results provides the GI of Gut plan microbiome information Utilizing making gut changes to discomfort Health that can some the patients briefly mention simple test their what collection wealth process ultimately and meaningful now in-market Gut to that improve personalized our our a analysis first your understand
experienced the by published IBS. This data after based in of taking with Medicine. collected patients Precision data that from supplements Clinical data to our score supporting The of irritable shows test, our technology bowel supported the use paper was the XXX.X% clinical Importantly, from guidance Gut Gut on the syndrome is test statistically Association. the or product from Health on behind XXX% reduction microbiome symptom Journal patients significant American the in published based a
or allows with that rapidly Our subgroups that surgical to personalized. to new provides shotgun or patients billions insights. has unique data us more identify metagenomic pharmaceutical who and such recover relevance fluids are differently and us drugs antibiotics sequence interventions. provides react allow from build as allows to more many prebiotics therapeutic This points from each to us across customer test areas could This of
I'd $XX.X of net million to the total which growth our am for review the high-level I represents to sales XX.X%. now for of a like provide quarter. financial year-over-year performance report quarter, first of pleased
of of direct-to-consumer XX% quarter revenues XXXX. of the first an business million, increase generated Our $XX.X over
at Our $XX grew Pro and in year-over-year. X.X% million and business-to-business revenues came by
of represents We more the growth end also rate. QX, active than of have XXX,XXX year-over-year which customers XX.X% subscribing as a
Our of higher from million adjusted were be QX and costs primarily declined adjusted marketing forecasts and from of spend growth. sales and $X.X clear, factored our from To year, these EBITDA we of see laid for well higher EPS selling last higher distribution improving as continued see out and expanding market margins We sales into progresses. we margins the while full-year committed guidance operating possible, to remain growth rates. the above XXXX, to we expect operating year where $X.XX
end expansion to our we've We plant expansion the outlined expect after of calls. significant the year, in as margin completing around occur prior
backorder gain five in in-house we use sustainability a of We the with program. among from construction issues have of reached liquid our also capacity five The propel our current demand. its expansion and current to production from globally new many time-to-time after of rapid likely our packaging caused high which puts capabilities ability and top unit scale based levels expansion, and our After of initiatives will will certain ceiling some introduce also capacity. of with following accelerate years margin the like of manufacturing. on goals support XXXX, facility on It's efficiencies our growth our completing ESG plant X.Xx into supplement our the will manufacturers us new personalized
outlook. to Turning our
campaign awareness, expect and to through increase which brand further product with the towards driven off footprint by supported as continuing ramp We the marketing small move be presently force our that our sales we kick third a expansion, international broadening sales to in recent by progress year, traction launches, quarter. will will
$X.XX. previously $XXX million of $XX $XXX sales result, reaffirming and margins of of between $X.XX XX% million guidance, are to EBITDA million adjusted for to a As million; which adjusted calls and to issued EPS we $XX our XX%, gross net
the on I'll prepared deployment call for remarks that, our results to of turn for priorities financial over the rest Saloni capital her the and With year.
